Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The Tumour Microenvironment and Epigenetic Regulation in BRCA1 Pathogenic Variant-Associated Breast Cancers.

Autor: Tay, Jun Yu¹ (AUTHOR), Ho, Josh Xingchong¹ (AUTHOR), Cheo, Fan Foon² (AUTHOR), Iqbal, Jabed² (AUTHOR) jabed.iqbal@singhealth.com.sg

Publikováno v: Cancers. Dec2024, Vol. 16 Issue 23, p3910. 19p.

The BRCA2 mutation status shapes the immune phenotype of prostate cancer.

Autor: Jenzer M; Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany.; Department of Medical Oncology, University of Heidelberg School of Medicine, National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany., Keß P; Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany., Nientiedt C; Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany.; Department of Medical Oncology, University of Heidelberg School of Medicine, National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany., Endris V; Institute of Pathology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany., Kippenberger M; Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany., Leichsenring J; Institute of Pathology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany., Stögbauer F; Institute of Pathology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany., Haimes J; ArcherDX, 2477 55th Street, Boulder, CO, 80301, USA., Mishkin S; ArcherDX, 2477 55th Street, Boulder, CO, 80301, USA., Kudlow B; ArcherDX, 2477 55th Street, Boulder, CO, 80301, USA., Kaczorowski A; Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany., Zschäbitz S; Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany.; Department of Medical Oncology, University of Heidelberg School of Medicine, National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany., Volckmar AL; Institute of Pathology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany., Sültmann H; National Center for Tumor Diseases, German Cancer Research Center, Cancer Genome Research, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Jäger D; Department of Medical Oncology, University of Heidelberg School of Medicine, National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany., Duensing A; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, USA.; Department of Pathology, University of Pittsburgh School of Medicine, 5117 Centre Avenue, Pittsburgh, PA, 15213, USA.; Section of Precision Oncology of Urological Malignancies, Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany.; Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany., Schirmacher P; Institute of Pathology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany., Hohenfellner M; Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany., Grüllich C; Department of Medical Oncology, University of Heidelberg School of Medicine, National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany.; Section of Translational Urooncology, Department of Medical Oncology, University of Heidelberg School of Medicine, National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany., Stenzinger A; Institute of Pathology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany. albrecht.stenzinger@med.uni-heidelberg.de., Duensing S; Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 517, 69120, Heidelberg, Germany. stefan.duensing@med.uni-heidelberg.de.; Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany. stefan.duensing@med.uni-heidelberg.de.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2019 Oct; Vol. 68 (10), pp. 1621-1633. Date of Electronic Publication: 2019 Sep 23.

1163P - Copy number variant detection by anchored multiplex PCR and next-generation sequencing

Autor: Haimes, J.D., Covino, J., Manoj, N., Baravik, E., Johnson, L., Griffin, L., Stahl, J., Myers, J.W., Culver, B., Kudlow, B.

Publikováno v: In Annals of Oncology 1 October 2016 27 Supplement 6:vi402-vi402